Menopause Spectrum EstroG-100
EstroG-100® was tested on pre, peri and post- menopausal American women in a randomized, double blind, placebo-controlled trial. To be eligible for the study, women had to have moderate or severe menopausal discomforts as identified by the Kupperman menopausal index (KMI), a questionnaire that evaluates a number of menopausal parameters including hot flashes/cold sweats, paresthesia (numbness and tingling), sleep interferences, nervousness, melancholia (sadness or gloom), vertigo (dizzy spells), occasional fatigue/weakness, palpitation (pounding of the heart), formication (sensation of crawling of the skin) and muscle or joint discomforts. A separate questionnaire assessed changes in vaginal dryness.
Study results demonstrated significant improvement. The average KMI score was significantly lower in the EstroG-100® group. The individual KMI scores that improved (compared to the control group) included hot flashes/cold sweats, paresthesia, sleep interferences, nervousness, melancholia, vertigo, occasional fatigue/weakness and muscle or joint discomfort. Vaginal dryness was also improved.